Effect of Multiple Dosing With BI 201335 on the Safety, Pharmacokinetics and Pharmacodynamics of Steady-state Methadone and Buprenorphine/Naloxone in Subjects on Stable Addiction Management Therapy

Trial Profile

Effect of Multiple Dosing With BI 201335 on the Safety, Pharmacokinetics and Pharmacodynamics of Steady-state Methadone and Buprenorphine/Naloxone in Subjects on Stable Addiction Management Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs Faldaprevir (Primary) ; Buprenorphine/naloxone; Methadone
  • Indications Hepatitis C; Opioid abuse
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Oct 2013 Results will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) according to a Boehringer Ingelheim media release.
    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Oct 2012 Planned End Date changed from 1 Oct 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top